EOM Pharmaceutical Holdings Inc IMUC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.20
- Day Range
- $0.16–0.20
- 52-Week Range
- $0.11–0.40
- Bid/Ask
- $0.16 / $0.39
- Market Cap
- $22.42 Mil
- Volume/Avg
- 1,730 / 3,679
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve the lives of patients suffering from debilitating and sometimes deadly diseases. Its pipeline includes compound EOM613, an investigational novel dynamically dual-acting immunomodulator. EOM613 is a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad-spectrum cytokine effects.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.eompharma.com
Valuation
|
Metric
|
IMUC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
IMUC
Financial Strength
|
Metric
|
IMUC
|
|---|---|
Quick Ratio | 8.31 |
Current Ratio | 9.53 |
Interest Coverage | — |
Quick Ratio
IMUC
Profitability
|
Metric
|
IMUC
|
|---|---|
Return on Assets (Normalized) | −97.59% |
Return on Equity (Normalized) | −324.91% |
Return on Invested Capital (Normalized) | −323.89% |
Return on Assets
IMUC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tkwgjwfqp | Vnbg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zjcflqyv | Ztnsc | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bxhdqhh | Ktskc | $97.8 Bil | |
MRNA
| Moderna Inc | Lqzqpgv | Yysc | $38.8 Bil | |
ARGX
| argenx SE ADR | Qfxkncmtp | Plkl | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Qrcllwryv | Zyjl | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lktdbtg | Gqlwjw | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hszmktrp | Cjcjn | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qjyntscyx | Mblmth | $12.5 Bil | |
INCY
| Incyte Corp | Kmbrbsnk | Qklqnyj | $11.5 Bil |